Company Overview - Skye Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing new therapeutic pathways for obesity and metabolic health disorders [1][3] - The company is conducting a Phase 2 clinical trial for nimacimab, a negative allosteric modulating antibody that inhibits CB1, and is also assessing its combination with a GLP-1R agonist (Wegovy®) [3] Upcoming Events - Skye will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare conference on January 16, 2025, from 10:30 AM to 11:10 AM [1] Research and Development Focus - Skye's strategy involves leveraging biologic targets with substantial human proof of mechanism to develop first-in-class therapeutics with clinical and commercial differentiation [3] - The company aims to unlock new therapeutic pathways through the development of next-generation molecules that modulate G-protein coupled receptors [3]
Skye Bioscience to Present at J.P. Morgan Healthcare Conference